drugset
drugset / Trial / NCT03857854

Efficacy and Safety of Pirfenidone in Patient With Dermatomyositis Interstitial Lung Disease (Dm-ILD)

NCT03857854 ↗

Phase 3 Unknown 152 enrolled Beijing Continent Pharmaceutical Co, Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of pirfenidone in subjects with dermatomyositis interstitial lung disease

Timeline

Start
2018-06-05
Primary completion
2021-02
Completion
2021-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Pirfenidone Small molecule — —

Indications

interstitial lung disease